Zydus Lifesciences Ltd

Zydus Lifesciences Ltd. has signed a Memorandum of Understanding (MoU) with Apollo Hospitals to expand access to the Shield™ Multi-Cancer Detection (MCD) test in India. This collaboration, facilitated by an exclusive agreement with Guardant Health, Inc., aims to make the methylation-based blood test available for detecting 10 common cancer types in individuals aged 45 and older. The Shield MCD test, which has received Breakthrough Device Designation from the U.S. FDA, screens for cancers including bladder, colorectal, breast, prostate, oesophageal, gastric, liver, lung, ovarian, and pancreas. This initiative is expected to improve early cancer detection rates in India, where cancer accounts for a significant portion of non-communicable disease deaths and screening rates are currently low.

Zydus Lifesciences Limited has announced a further extension for the acquisition of Sterling Biotech Limited's (SBL) API business. Originally expected to close by December 31, 2024, the closing date was previously extended to June 30, 2026. Now, due to SBL's ongoing process of fulfilling certain conditions precedent, the parties have agreed to extend the closing date to September 30, 2026. The transaction is now anticipated to be completed on or before this new date.

Zydus Lifesciences Limited has entered into a Share Subscription and Shareholders' Agreement with Sunshine Healthcare Lanka Limited to form a 50:50 joint venture, Zydus Sunshine Lifesciences (Private) Limited. The JV will focus on manufacturing pharmaceutical products in Sri Lanka, aiming to strengthen local production and reduce import dependence. Zydus will invest up to USD 5 million in tranches. The new entity, Zydus Sunshine, is recently incorporated and has no prior turnover. The transaction is expected to be completed within 90 working days and is not considered a related party transaction.

Zydus Lifesciences Limited has announced the closure of its trading window for Directors and Designated Persons, along with their immediate relatives. The window will be shut from Wednesday, July 1, 2026, until 48 hours after the declaration of the unaudited financial results for the quarter ending June 30, 2026. This measure is in accordance with the company's Code of Insider Trading to prevent potential misuse of unpublished price-sensitive information. The date for the Board meeting to approve these financial results will be communicated separately.

Zydus Lifesciences Ltd has disclosed under SEBI (Prohibition of Insider Trading) Regulations, 2015, that its promoters, promoter group, directors, and their immediate relatives have accepted equity shares for buyback. The Zydus Family Trust, a significant promoter, tendered 63,49,542 shares, representing a substantial portion of their holding. Other entities and individuals within the promoter group and management also participated, with their shareholding percentages remaining largely stable post-buyback due to the proportionate acceptance basis. The buyback price was ₹1,260 per equity share.

Zydus Lifesciences Limited has announced the completion of its share buyback program. The company repurchased 87,30,158 equity shares, representing 0.87% of its paid-up capital, at a price of ₹1,260 per share. The total buyback size amounted to ₹1,100 crore. This action was conducted on a proportionate basis through a tender offer route, in compliance with SEBI regulations. The company has published a post-buyback advertisement in English, Hindi, and Gujarati newspapers to inform shareholders.

Zydus Lifesciences Limited has announced the successful completion of its merger with Assertio Holdings Inc. through its wholly owned subsidiary, Zara Merger Sub Inc. Following the merger, Assertio has become a wholly owned subsidiary of Zydus Lifesciences, and its common stocks are no longer listed on the Nasdaq Global Market. The acquisition involved an offer price of USD 23.50 per share in cash, with a total consideration of USD 166.33 million. Assertio is a US-based specialty oncology pharmaceutical company with a key product, ROLVEDON®, approved by the USFDA. This strategic move aims to acquire outstanding shares and gain full control over Assertio.

Zydus Lifesciences Ltd. has successfully completed the acquisition of Assertio Holdings, Inc. through its wholly-owned subsidiary, Zara Merger Sub Inc. The cash tender offer, priced at $23.50 per share, saw 66.32% of Assertio's shares tendered. Following the merger, Assertio will become a wholly-owned subsidiary of Zydus, and its shares will be delisted from the Nasdaq Global Market. This strategic move aims to expand Zydus's global healthcare offerings.

Zydus Lifesciences Ltd announced that its wholly-owned subsidiary, Zydus Healthcare Limited (ZHL), has received favorable orders from the Appellate Additional Commissioner of State, Chhattisgarh. This ruling partially drops a Goods and Services Tax (GST) demand and penalty related to Input Tax Credit (ITC) for FY 2018-19 and FY 2019-20. The initial demand for FY 2018-19 was ₹28.7 lakhs, which has been reduced to ₹0.24 lakhs. For FY 2019-20, the initial demand of ₹13.2 lakhs has been reduced to ₹0.20 lakhs. This outcome represents a significant reduction in the financial liability for the subsidiary.

Zydus Lifesciences Ltd announced it has received a Warning Letter from the USFDA concerning its Baddi facility. The letter relates to technical observations on the use of purified talc not meeting USP requirements and was issued following a request for records, not an on-site inspection. The company believes this will not impact current operations or supplies from the site. The Baddi facility's last USFDA inspection in August 2025 resulted in a Voluntary Action Indicated (VAI) status. Zydus is committed to addressing the remediation steps promptly.